Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[surf1944]

7:02AM Ligand Pharma signs global license agreement with Spectrum Pharmaceuticals (SPPI) for Captisol-enabled melphalan (LGND) 21.86 : Co announced the signing of global license and supply agreements with Spectrum Pharmaceuticals (SPPI) for the development and commercialization of Ligand's Captisol-enabled, propylene glycol-free melphalan. Under the terms of the license agreement, Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestone payments. Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan.